Human papillomavirus type 6 E7 protein-derived peptide epitopes presented on major histocompatibility complex molecules (HPV6 E7-MHC)

The Human Papillomavirus type 6 (HPV6) E7 protein-derived peptide epitopes presented on major histocompatibility complex (MHC) molecules represent a specialized class of immunotherapy targets for treating low-risk HPV-associated diseases (UniProt P06465). HPV6 is the primary driver of recurrent respiratory papillomatosis (RRP) and condyloma acuminatum, which cause significant morbidity despite their low oncogenic potential (PubMed: 29107557). The E7 oncoprotein is essential for the viral life cycle, acting to destabilize the retinoblastoma protein (pRb) and force host cells into the S-phase of the cell cycle (PubMed: 10482588). In infected cells, E7 is processed into short peptides and presented on the cell surface by MHC Class I molecules, creating a unique molecular signature for T-cell recognition. Current clinical development focuses on therapeutic vaccines, such as the DNA-based INO-3106 and the adenoviral-vectored PRGN-2012, which aim to induce a robust, antigen-specific CD8+ T-cell response (ClinicalTrials.gov: NCT04398420, NCT04724980). These therapies are designed to overcome the immune tolerance often observed in chronic HPV infections by providing a potent stimulus to clear E7-expressing cells. The specificity of this target minimizes damage to healthy, non-infected tissues, although viral mechanisms of MHC downregulation remain a challenge for efficacy.

Other names

HPV6 E7 antigenHPV6 E7 HLA-peptide complexHuman papillomavirus 6 E7 epitopesHPV6 E7 peptide-MHC complex

Induction of antigen-specific cytotoxic T-lymphocyte responses against cells presenting HPV6 E7 peptides on MHC molecules.